文献速递心力衰竭与心肌病血脂与心血管预防

转甲状腺素蛋白淀粉样变心肌病患者的肾脏结局

Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该回顾性单中心队列研究纳入2001年至2024年英国国家淀粉样变中心诊断的2001例ATTR-CM患者,评估1年内eGFR下降>20%与全因死亡风险的关系。结果显示24.0%患者出现肾功能下降,其与1.7倍死亡风险独立相关,且不受基因型或疾病分期影响。

要点

  • ATTR-CM患者1年内eGFR下降>20%者占24.0%,与全因死亡风险增加独立相关。
  • 肾功能下降与死亡风险的关联在野生型、p.(V142I)及非p.(V142I)基因型中一致。
  • eGFR下降是ATTR-CM疾病进展的独立标志物,可指导治疗优化。

核心结论

  • 在ATTR-CM患者中,肾功能下降频繁发生,且与全因死亡风险增加 consistently 相关,即使调整已确立的ATTR-CM恶化标志物后仍独立相关。
  • eGFR下降代表ATTR-CM疾病进展的独立标志物,可指导临床实践中的治疗优化。

研究设计与样本

  • 回顾性、观察性、单中心队列研究,纳入2001年1月至2024年4月英国国家淀粉样变中心诊断的ATTR-CM患者,均完成基线及1年随访eGFR评估,共2001例。
  • 数据分析于2024年6月进行。

主要发现

  • 患者平均(SD)年龄75.5(8.4)岁,女性263例(13.1%)。
  • eGFR中位(IQR)变化为-5 mL/min/1.73 m2(-12至1),481例(24.0%)出现肾功能下降(定义为eGFR下降>20%)。
  • 肾功能下降组较稳定组更常见p.(V142I)基因型(99例[20.6%] vs 202例[13.3%];P < .001),且基线心脏表型更严重:NT-proBNP中位(IQR)2949 pg/mL(1759-5182) vs 2309 pg/mL(1146-4290),P < .001;肌钙蛋白T中位(IQR)0.060 ng/mL(0.042-0.086) vs 0.052 ng/mL(0.033-0.074),P < .001;基线eGFR中位(IQR)63 mL/min/1.73 m2(51-77) vs 61 mL/min/1.73 m2(49-77),P = .41。
  • 肾功能下降与死亡风险增加1.7倍相关(HR 1.71;95% CI 1.43-2.04;P < .001),且在3种基因型(野生型:HR 1.64;95% CI 1.31-2.04;p.(V142I):HR 1.70;95% CI 1.21-2.39;非p.(V142I):HR 1.51;95% CI 0.87-2.61;交互作用P = .93)及3个NAC疾病分期(1期:HR 1.69;95% CI 1.22-2.32;2期:HR 1.69;95% CI 1.30-2.18;3期:HR 1.61;95% CI 1.11-2.35;交互作用P = .97)中风险相似。
  • 调整NT-proBNP升高和门诊利尿剂强化后,肾功能下降仍独立与死亡相关(HR 1.48;95% CI 1.23-2.76;P < .001)。

临床怎么用

  • 在ATTR-CM患者中应监测eGFR变化,1年内下降>20%提示疾病进展风险增加,可考虑强化治疗。
  • 肾功能下降的预后价值不受基因型或疾病分期影响,各亚组患者均应关注。

局限性

  • 回顾性、观察性、单中心研究设计可能引入选择偏倚和残留混杂。
  • 肾功能下降定义基于1年随访eGFR评估,未涉及更长期或多次评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cardiomyopathy that commonly presents with concomitant chronic kidney disease. Chronic kidney dysfunction is associated with worse outcomes, but the prognostic value of changes in kidney function over time has yet to be defined. OBJECTIVE: To assess the prognostic importance of a decline in estimated glomerular filtration rate (eGFR) in a large cohort of patients with ATTR-CM. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, observational, single-center cohort study evaluated patients diagnosed with ATTR-CM at the National Amyloidosis Centre (NAC) in the UK who underwent an eGFR baseline assessment and a follow-up assessment at 1 year between January 2000 and April 2024. Data analysis was performed in June 2024. MAIN OUTCOMES AND MEASURES: The primary outcome was the risk of all-cause mortality associated with decline in kidney function (defined as a decrease in eGFR >20%). RESULTS: Among 2001 patients, mean (SD) age was 75.5 (8.4) years, and 263 patients (13.1%) were female. The median (IQR) change in eGFR was -5 mlL/min/1.73 m2 (-12 to 1), and 481 patients (24.0%) experienced decline in kidney function. Patients who experienced decline in kidney function more often had the p.(V142I) genotype than patients with stable kidney function (99 [20.6%] vs 202 [13.3%]; P < .001) and had a more severe cardiac phenotype at baseline, as evidenced by higher median (IQR) concentrations of serum cardiac biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP]: 2949 pg/mL [1759-5182] vs 2309 pg/mL [1146-4290]; P < .001; troponin T: 0.060 ng/mL [0.042-0.086] vs 0.052 ng/mL [0.033-0.074]; P < .001), while baseline median (IQR) kidney function was similar between the 2 groups (eGFR: 63 mL/min/1.73 m2 [51-77] vs 61 mL/min/1.73 m2 [49-77]; P = .41). Decline in kidney function was associated with a 1.7-fold higher risk of mortality (hazard ratio [HR], 1.71; 95% CI, 1.43-2.04; P < .001), with a similar risk across the 3 genotypes (wild type: HR, 1.64; 95% CI, 1.31-2.04; p.(V142I): HR, 1.70; 95% CI, 1.21-2.39; non-p.(V142I): HR, 1.51; 95% CI, 0.87-2.61) (P for interaction = .93) and the 3 NAC disease stages (stage 1: HR, 1.69; 95% CI, 1.22-2.32; stage 2: HR, 1.69; 95% CI, 1.30-2.18; stage 3: HR, 1.61; 95% CI, 1.11-2.35) (P for interaction = .97). Decline in kidney function remained independently associated with mortality after adjusting for increases in NT-proBNP and outpatient diuretic intensification (HR, 1.48; 95% CI, 1.23-2.76; P < .001). CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, decline in kidney function was frequent in patients with ATTR-CM and was consistently associated with an increased risk of mortality, even after adjusting for established markers of worsening ATTR-CM. eGFR decline represents an independent marker of ATTR-CM disease progression that could guide treatment optimization in clinical practice.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Ioannou A, Razvi Y, Porcari A, et al. Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy. JAMA Cardiol. 2025. PMID: 39550765. doi:10.1001/jamacardio.2024.4578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。